Results 141 to 150 of about 30,536 (239)

Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia

Journal of Blood Medicine, 2015
Christopher Arthur,1 Jaroslav Cermak,2 Jacques Delaunay,3 Jirí Mayer,4 Grzegorz Mazur,5 Xavier Thomas,6 Agnieszka Wierzbowska,7 Mark M Jones,8 Erhan Berrak,8 Hagop Kantarjian9 1Department of Haematology, Royal North Shore Hospital, Sydney, NSW ...
Arthur C, Cermak J, Delaunay J, Mayer J, Mazur G, Thomas X, Wierzbowska A, Jones MM, Berrak E, Kantarjian H   +9 more
doaj  

Morphological evaluation of dysmyelopoiesis in decitabine-treated patients with myelodysplastic syndromes

Терапевтический архив, 2013
AIM: To estimate a change in myelodysplasia in decitabine-treated patients with myelodysplastic syndromes (MDS)/MATERIAL AND METHODS: Thirteen MDS patients from a high-risk group were examined; 75 bone marrow puncture specimens and 67 bone marrow ...
V N Dvirnyk, A V Kokhno, E N Glasko, É G Gemdzhian, O A Diagileva, T L Platonova, E N Parovichnikova   +6 more
doaj  

The effects of adding decitabine to conditioning regimen for patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. [PDF]

Ann Hematol
Luo C, Zhang J, Huang X, Wu G, Huang Y, Ding Y, Huang Z, Song Q, Chen J, Li X, Xu S.   +10 more
europepmc   +1 more source

Survival predictors in Vietnamese elderly AML patients treated with decitabine: Real-world evidence from a low- and middle-income country. [PDF]

Leuk Res Rep
Nguyen HT, Bach QK, Nguyen QN, Nguyen VN, Nguyen TVA, Pham-The H.   +5 more
europepmc   +1 more source

Prognostic value of BTG1 for predicting decitabine sensitivity in <i>de novo</i> acute myeloid leukemia. [PDF]

iScience
Zhang S, Li M, Xu B, Zhu X, Mao X, Zhou H, Tong X, Su S, Zhu Y, Zhang D.   +9 more
europepmc   +1 more source

Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-Escalation Trial. [PDF]

Cancers (Basel)
Handa S, Koenig K, Zhao Q, Mims AS, Vasu S, Garzon R, Haque T, Benson D, Klisovic RB, Marcucci G, Walker AR, Bhatnagar B.   +11 more
europepmc   +1 more source

Combining drugs that bypass p53 to treat TP53-mutated leukemias. [PDF]

Blood Adv
Biswas S, Zahran ZAM, Gu X, Cardone L, Marti R, Mouannes N, Stich M, Jain A, Fedorov K, Tomlinson B, Goldfinger M, Verma A, Saunthararajah Y.   +12 more
europepmc   +1 more source

Decitabine promotes degradation of DNMT1 and EZH2 via the ubiquitination pathway and inhibits colorectal cancer progression. [PDF]

Cell Oncol (Dordr)
Peng XM, Shi XP, Chen H, Cao LY, Zuo HJ, Guo JQ, Jiang N, Luo XY.   +7 more
europepmc   +1 more source

Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study

Leukemia, 2020
P. Montesinos, G. Roboz, C. Bulabois, M. Subklewe, U. Platzbecker, Y. Ofran, C. Papayannidis, A. Wierzbowska, H. Shin, V. Doronin, Stefan Deneberg, S. Yeh, M. Ozcan, S. Knapper, Jorge Cortes, D. Pollyea, G. Ossenkoppele, S. Giralt, H. Döhner, M. Heuser, L. Xiu, I. Singh, F. Huang, J. Larsen, A. Wei   +24 more
semanticscholar   +1 more source

Disordered DNA methylation leads to targetable transcriptional plasticity in ATRT. [PDF]

Acta Neuropathol Commun
Tetens AR, Findlay TR, Craig-Schwartz J, Liapodimitri A, Camacho O, Skalitzky KO, Idrizi A, Tryggvadottir R, Lunsford K, Raabe EH, Koldobskiy MA.   +10 more
europepmc   +1 more source